Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVN NASDAQ:CNTA NASDAQ:LEGN NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$12.12-0.2%$10.09$7.48▼$18.57$1.83B1.352.96 million shs2.38 million shsCNTACentessa Pharmaceuticals$39.750.0%$39.65$12.30▼$40.26$6.15B1.111.18 million shs2.22 million shsLEGNLegend Biotech$33.38-5.9%$26.97$16.24▼$45.30$6.59B0.352.67 million shs2.01 million shsPTCTPTC Therapeutics$73.27-4.6%$70.83$43.17▼$87.50$6.37B0.561.24 million shs6.04 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven-0.17%+9.05%+38.58%+33.32%-20.25%CNTACentessa Pharmaceuticals-0.03%-0.03%+0.40%+38.45%+215.48%LEGNLegend Biotech-5.92%-0.33%+21.16%+83.31%-6.86%PTCTPTC Therapeutics-4.56%-0.56%+2.52%+9.36%+41.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$12.12-0.2%$10.09$7.48▼$18.57$1.83B1.352.96 million shs2.38 million shsCNTACentessa Pharmaceuticals$39.750.0%$39.65$12.30▼$40.26$6.15B1.111.18 million shs2.22 million shsLEGNLegend Biotech$33.38-5.9%$26.97$16.24▼$45.30$6.59B0.352.67 million shs2.01 million shsPTCTPTC Therapeutics$73.27-4.6%$70.83$43.17▼$87.50$6.37B0.561.24 million shs6.04 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven-0.17%+9.05%+38.58%+33.32%-20.25%CNTACentessa Pharmaceuticals-0.03%-0.03%+0.40%+38.45%+215.48%LEGNLegend Biotech-5.92%-0.33%+21.16%+83.31%-6.86%PTCTPTC Therapeutics-4.56%-0.56%+2.52%+9.36%+41.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 2.71Moderate Buy$22.2783.78% UpsideCNTACentessa Pharmaceuticals 2.21Hold$41.333.98% UpsideLEGNLegend Biotech 2.67Moderate Buy$60.2380.44% UpsidePTCTPTC Therapeutics 2.71Moderate Buy$91.3624.69% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, LEGN, PTCT, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.006/3/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026LEGNLegend Biotech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $49.006/3/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $65.006/2/2026BHVNBiohaven Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/1/2026LEGNLegend Biotech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $50.005/27/2026BHVNBiohaven Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy5/27/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.005/26/2026BHVNBiohaven HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$10.005/20/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/ACNTACentessa Pharmaceuticals$15M409.85N/AN/A$3.92 per share10.14LEGNLegend Biotech$1.03B6.03N/AN/A$5.43 per share6.15PTCTPTC Therapeutics$1.73B3.51$8.37 per share8.75($2.56) per share-28.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)CNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.68N/A18.44N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A34.733.53-22.58%-362.45%-6.76%8/6/2026 (Estimated)Latest BHVN, LEGN, PTCT, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/A3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohaven1.877.417.41CNTACentessa Pharmaceuticals0.239.539.53LEGNLegend BiotechN/A2.132.05PTCTPTC TherapeuticsN/A2.442.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%CNTACentessa Pharmaceuticals82.01%LEGNLegend Biotech70.89%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipBHVNBiohaven13.80%CNTACentessa Pharmaceuticals4.09%LEGNLegend Biotech0.02%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239150.56 million129.78 millionOptionableCNTACentessa Pharmaceuticals200154.66 million148.34 millionOptionableLEGNLegend Biotech2,965185.74 million185.70 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableBHVN, LEGN, PTCT, and CNTA HeadlinesRecent News About These CompaniesPTC Therapeutics (NASDAQ:PTCT) Sees Strong Trading Volume - Time to Buy?June 16 at 11:31 AM | marketbeat.comPTC Therapeutics, Inc.: PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible NotesJune 16 at 10:01 AM | finanznachrichten.dePTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible NotesJune 15 at 11:14 PM | prnewswire.comPTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible NotesJune 15 at 7:00 AM | prnewswire.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $1,595,775.00 in StockJune 15 at 4:13 AM | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Insider Sells $1,595,775.00 in StockJune 13, 2026 | insidertrades.com96,860 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Castleark Management LLCJune 13, 2026 | marketbeat.comSector Gamma AS Sells 56,189 Shares of PTC Therapeutics, Inc. $PTCTJune 12, 2026 | marketbeat.comLos Angeles Capital Management LLC Has $2.46 Million Stock Position in PTC Therapeutics, Inc. $PTCTJune 10, 2026 | marketbeat.comPTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.com19,877 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Commonwealth of Pennsylvania Public School Empls Retrmt SYSJune 8, 2026 | marketbeat.comWhy The PTC Therapeutics (PTCT) Story Is Shifting As Sephience Assumptions Drive New ValuationsJune 7, 2026 | finance.yahoo.comBI Asset Management Fondsmaeglerselskab A S Purchases 64,472 Shares of PTC Therapeutics, Inc. $PTCTJune 7, 2026 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from BrokeragesJune 7, 2026 | marketbeat.comGeode Capital Management LLC Boosts Stake in PTC Therapeutics, Inc. $PTCTJune 5, 2026 | marketbeat.comBNP Paribas Financial Markets Has $62.95 Million Stock Holdings in PTC Therapeutics, Inc. $PTCTJune 2, 2026 | marketbeat.comLegal & General Group Plc Buys 124,923 Shares of PTC Therapeutics, Inc. $PTCTJune 1, 2026 | marketbeat.comPTC Therapeutics, Inc. $PTCT Shares Sold by Hillsdale Investment Management Inc.May 31, 2026 | marketbeat.comJupiter Asset Management Ltd. Makes New $27.43 Million Investment in PTC Therapeutics, Inc. $PTCTMay 30, 2026 | marketbeat.comRoyce & Associates LP Increases Stock Holdings in PTC Therapeutics, Inc. $PTCTMay 30, 2026 | marketbeat.comPTC Therapeutics upgraded at Jefferies on SephienceMay 27, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, LEGN, PTCT, and CNTA Company DescriptionsBiohaven NYSE:BHVN$12.12 -0.02 (-0.20%) Closing price 06/16/2026 03:59 PM EasternExtended Trading$12.02 -0.09 (-0.75%) As of 06/16/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Centessa Pharmaceuticals NASDAQ:CNTA$39.75 -0.01 (-0.03%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$39.76 +0.01 (+0.01%) As of 06/16/2026 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Legend Biotech NASDAQ:LEGN$33.38 -2.10 (-5.92%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$33.23 -0.15 (-0.45%) As of 06/16/2026 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.PTC Therapeutics NASDAQ:PTCT$73.27 -3.50 (-4.56%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$73.24 -0.03 (-0.05%) As of 06/16/2026 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
